Zydus Cadila has received an approval from the USFDA for Hydroxychloroquine Sulfate Tablets in the strength of 200 mg. The drug falls in the DMARD (Disease Modifying Anti-Rheumatic Drug) segment and is used in the management of rheumatoid arthritis. The sales of Hydroxychloroquine Sulfate Tablets in the US market in 2006 as per NDC Health was estimated at USD $ 30 mn.
The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group has 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs.
